RÉPUBLIQUE FRANÇAISE
Liberté
Égalité
Fraternité

Inserm
La science pour la santé
From science to health

HR EXCELLENCE IN RESEARCH

CALL FOR APPLICATION

INSERM CHAIR Recruitment

Study of alternative splicing in the healthy and malignant hematopoietic system - (HemOSpl

The Inserm chair recruitments opened to Inserm are intended for researchers with strong potential to manage and lead research teams and participate in national, European or international projects.

This recruitment, based on research and teaching projects, is aimed at researchers with a doctorate or equivalent and a first post-doctoral experience. The position is offered on a fixed-term contract (CDD) with a view to tenure in the Inserm Research Directors personnel at the end of the contract.

How apply: https://pro.inserm.fr

Supporting institution:	Inserm : Institut national de la Santé et de la recherche médicale
Name of the head of the institution:	Pr. Didier Samuel
Academic region:	ILE-DE-FRANCE
Location/ Site concerned:	Inserm U1342 Inserm, Institut de Recherche Saint-Louis (IRSL, hôpital Saint-Louis) - Paris
Partner institution:	Université Paris-Cité
Research contact:	Jean SOULIER: jean.soulier@aphp.fr
Administrative contact:	chaires-professeur-junior@inserm.fr
Research fields EURAXESS:	Medical sciences. Stem cells, leukemia/cancers (Medical sciences)
Keywords:	Alternative splicing, myelodysplastic syndromes, leukemias, stem cells, endoplasmic reticulum stress

Job title to be filled:	Chaire - Study of alternative splicing in the healthy and malignant hematopoietic system - (HemOSpl
Body after tenure:	Research Director
Anticipated duration of the contract:	5 years
Scientific domains/fields:	Stem cells, leukemia/cancers

Corresponding specialized scientific commissions (CSS):	CSS1 - Cellular, molecular and structural biology CSS2 - Oncology, genetic diseases
Project name:	Study of alternative splicing in the healthy and malignant hematopoietic system - (HemOSpl

Remuneration package	3 500€ - 5 000€ according to research experience
Quota	Full Time

Strategy of the host institution:

The French National Institute for Health and Medical Research (INSERM) is the central organization for research in human health in France. The research conducted by INSERM covers all fields of biomedical research, from basic to highly applied research at the heart of the healthcare system and public health expertise.
As a founder of Saint-Louis Research Institute (IRSL) and IHU THEMA (The Paris Saint-Louis Leukemia Institute), Inserm supports the field of research in cancerology and hematology. IRSL is a major player of national and international translational research in malignant hematology, especially acute leukemia. Research programs such as the IHU THEMA or the SIRIC InSitu will support transversal actions (data collection and sample biobanking, functional screen, technical platforms including single cell analysis, institute organization, valorization, communication and outreach), with the final aim to cure leukemia by bridging basic and clinical research and developing innovative strategies. This developement strategy needs support to cover the core salary of new PI that will join the Institute.

Strategy of the host laboratory:

Research at the IRSL / U1342 is largely dedicated to onco-hematology, supported by the IHU THEMA and Siric InSitu project. Fastrack pipelines are efficient to deliver to the teams highly annotated samples from patients and clinical information from the National trials on leukemia and related diseases (myelodysplastic syndromes and aplasia). High profile research teams, including 4 current or past ERC teams, address pathophysiology of acute leukemia (de Thé, Puissant, Clappier, Benajiba, Itzykson), aplasia/leukemia predisposition (Soulier) and myeloproliferative neoplasia (Giraudier), but there is a lack of research on hematopoietic stem cells and myelodysplastic syndromes. Alternative splicing deregulation is clearly instrumental in normal and malignant HSC development, but their role is still elusive. Elucidating the role of alternative splicing deregulation will open avenues for precision medicine staging, prognosis, and leukemia prevention and treatment. There will be tight interactions between the « Chaire Professor Junior » researcher and other PI and researchers on site. The CPJ position laureate will benefit from all technical and animal experimention platforms from the Institute and common tolls and expertise within the IRSL community.

Summary of the scientific project:

The haematopoietic system provides, through differentiation and expansion of haematopoietic stem cells (HSCs), all blood cells for the life span of an individual. Despite its fundamental role in life and curative impact in disease, our understanding of the human haematopoietic system remains elusive. While in the past two decades, the widespread use of transcriptomics has catalogued genes expression in HSCs and progenitors, little is still understood about the alternatives splicing that govern the haematopoietic system. In order to provide new layers of molecular identity and behaviour of human HSCs that contribute to developmental and malignancies regulation, the research programme will have to answer two fundamental questions: (1) What are the alternatives splicing that regulate normal and malignant Haematopoietic Stem and Progenitor cells (HSPCs)? (2) How mechanisms driving alternative splicing control the haematopoietic system?

Summary of the teaching project:

The CPJ laureate will contribute to the various malignant hematology education programs set up by the site within the frame of the University Paris Cité: Ecole doctorale *Hematology Oncology Biotherapy*, several masters modules in Oncology and the overall MD-PhD training path.

National Research Agency package: 200k€

Other package:

Co-funding* : Package IHU THEMA-1 (already secured at the University Paris Cité, ANR IHUB) 325k€

*source et montant

Scientific dissemination/ Open Science:

Scientific communication and dissemination:

The research outputs will have to be communicated using traditional routes for the dissemination of academic research, including publication in peer-reviewed journals and presentations in national and international conferences such as the French society of haematology (SFH), the European Hematology Association and the American Society of Hematology (ASH) respectively.

Any promising prognostic signature/molecular biomarkers, new technologies and patentable findings obtained from the experimental approaches and validated in accordance with Biomarker Roadmaps and research good practice, will be discussed with the transfer of technology department for potential patent and commercial partnerships.

Open Science:

Research Integrity

Prior starting any work in the laboratory, all staff will have to receive: health and safety training, adequate induction for good lab practice, including a training on research integrity and misconduct in science.

Data sharing

New models generated will be banked at the Institut de Recherche Saint Louis and will be made available to other researchers upon request through this facility after publication and material of transfer agreement, including cell lines and new murine models. All vectors and plasmid generated will be deposited on Addgenes. All high-throughput sequencing data will be submitted to NCBI-GEO or EMBL-EBI and access will be made possible upon request.

Publications

Open access publications will be secured.

Science and society:

The candidate is expected to use the route of communications available at the host institute. For instance, the University of Paris-Cite has an established Media Centre that employs a dedicated team of public relation officers that actively disseminate developments and research findings arising from research within the university to the wider public. These resources will be used to disseminate the outcome of the candidate's research to the wider public by press releases in the Institut de recherche Saint Louis and Paris-Cite.

The work will have to be translational, therefore engagement with clinicians at the institute and hospital is essential for the adoption of new therapies and methodologies. The Saint-Louis clinical community will have to be updated through annual seminars. New methodologies and findings on combination treatments will also be presented to the international scientific and non-scientific (clinicians, patient support groups) community in appropriate forums. This will be achieved by presenting the outcomes of this research in conferences attended by clinicians, such as the French Society of Hematology (SFH), the European Hematology Association (EHA), the American Association for Cancer Research (AACR) and the American Society of Hematology (ASH) in the United States.

Indicators:

To review the progress on the project, starting from year two an annual meeting will review the progress of the project with internal members such as Professors Jean Soulier, Hugues De Thé, Raphael Itzykson, Lionel Ades and Drs Alexandre Puissant, Camille Lobry and Lina Benajiba. The meeting will review the progress made on the different objectives and discuss potential amendments to the project.

Teaching: List of teaching (Graduate school or Doctorate School, internal seminars)

Research: presentations at international conferences and Institute's invitations ; PhD students and post-doc hired ; other grants to the CPJ PI (from and out from the IHU THEMA) ; Articles.

Knowledge transfer: list of active collaborations, publicly available dataset.

Selection of candidates:

It is expected the recruited researcher to become rapidly a group leader in the GAD team. So the candidate should demonstrate ability to supervise Ph.D students, post-doctoral fellow and technical support staff. She/he should have the capacity to obtain competitive funding to manage her/his group.

Successful candidates are chosen by a selection commission composed of six to ten members, the majority of whom are specialists in the fields of research concerned.

The commission carries out an initial examination of the applications, focused in particular on candidate experience and skills relative to the research and teaching project presented above. A shortlist of candidates is then selected for interview.
Only candidates selected by the selection committee on the basis of their applications will be invited to interview.

The interviews are followed by a deliberation during which selection commission will discuss the quality, originality and, where appropriate, the interdisciplinarity of the research and teaching projects presented by the candidates, their motivation and their scientific and teaching supervision capacity.

The candidates selected at the end of the selection process will be offered a researcher contract, following approval from the President and CEO of Inserm.

Required profile:

Education Level: **Phd**

Researcher Profile: R3/R4

R3 Established researcher A stage in a researcher's career describing those who have developed a level of independence and can described as an established researcher
R4 Leading Research A stage in a researcher's career where they can be termed a 'leading researcher'. This would include the team leader of a research group or head of an industry R&D laboratory.

Your application will be evaluated according to the following criteria:

- Relevance and originality of the project related to the research field
- International exposure in research projects
- Your ability to raise funds
- Participation in editorial and reviewing activities
- Your teaching experience
- Your ability to lead a team…

Application instruction:

Applications can be submitted online at EVA.
Deadline application: **September 2, 2025**

Please complete the scientific file in English.

It is imperative to contact the laboratory corresponding to the Chair you have applied for in order to build the project with them.

Position also open to 'Bénéficiaires de l'Obligation d'Emploi' (disabled persons), as defined in article 27 of law no. 84-16 of January 11, 1984 on statutory provisions for the civil service.